All In Biotech

Drug Trial Radar · NCT07138846

A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

A Randomized, Double-blind, Multi-center, Phase III Study of MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

231

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Lepu Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, multi-center, phase III study to evaluate the efficacy and safety, pharmacokinetic profile and immunogenicity of MRG004A in patients with advanced pancreatic cancer.

Conditions

  • Advanced Pancreatic Cancer

Interventions

  • MRG004A plus best supportive careDrug

    MRG004A will be administrated as specified in the protocol.

  • Placebo plus best supportive careDrug

    Placebo will be administrated as specified in the protocol, following the same dose regimen as MRG004A.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Baseline to study completion (up to 24 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.